Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.
Condition: Interstitial Lymphocytic Lung Disease Interventions: Drug: Rituximab; Drug: Abatacept Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Abatacept | Allergy & Immunology | Cancer & Oncology | Children | Hematology | Orencia | Pediatrics | Primary Immunodeficiency Disease | Research | Rituxan